Immunomodulators for the prevention and treatment of acute respiratory infections: Efficacy of azoximer bromide

Булгакова, В.А.

doi:10.17116/terarkh2014861292-97

Cited by 5 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8,9 Along with vaccines, an effective method for preventing influenza and ARVI is the use of antiviral drugs, such as specific antiviral chemotherapeutic agents, local interferons, and antiviral immunomodulators. [10][11][12][13][14] The number of resistant strains of the influenza virus is constantly increasing; therefore, it is not recommended using neuraminidase inhibitors (oseltamivir, zanamivir) for the chemoprevention of both seasonal influenza caused by known strains and pandemic influenza, as it may result in large-scale influenza outbreaks or epidemics that are difficult to manage. 15 Inhibitors of M2-protein of the influenza A that are not effective against influenza B (amantadine and rimantadine) are not currently recommended for the treatment or prevention of influenza because of high levels of resistance shown in the recent studies.…”

Section: Introductionmentioning

confidence: 99%

Pharmacologic and Epidemiologic Study of the Course of Influenza and Other Acute Respiratory Viral Infections in Postpandemic Season in Children Younger than 18 years

Булгакова

Учайкин

Шамшева

et al. 2016

J Pediatr Infect Dis

View full text Add to dashboard Cite

Introduction?We assessed the epidemiologic data of influenza and other acute respiratory viral infections in children during the first postpandemic season. Methods?A retrospective analysis of randomly selected case histories of 2044 children with influenza and other ARVI. Results?Influenza A was diagnosed in 40%, influenza B in 12%, and other ARVI in 10% of cases. Umifenovir (Arbidol) was the most frequently prescribed at the prehospital and hospital stages (10.2% [207/2,025] and 65.2% [1,332/2,042], respectively). Conclusion?The results suggested that early prescription of Arbidol significantly reduced the duration of the main symptoms of influenza and ARVIs and the risk of complications.

show abstract

Section: Introductionmentioning

confidence: 99%

Pharmacologic and Epidemiologic Study of the Course of Influenza and Other Acute Respiratory Viral Infections in Postpandemic Season in Children Younger than 18 years

Булгакова

Учайкин

Шамшева

et al. 2016

J Pediatr Infect Dis

View full text Add to dashboard Cite

show abstract

Interferoncontaining drugs: clinical, pharmacological, and immunological points of their use for respiratory diseases treatment

et al. 2021

View full text Add to dashboard Cite

Nowadays pharmacological group classified by the ATX L03AX code as immunostimulants is demand among doctors of various specialties. The main area of application of such drugs is infectious respiratory viral processes, which are associated not only with the pathogenetic action of viruses, but also with a high risk of bacterial complications. Thus, the practitioner is faced with the task of preventing such complications and choosing an immunomodulatory drug with the most pronounced pharmacodynamic properties in this regard. In Russia, there are many drugs belonging to the group of immunomodulators with different mechanisms of action and end pharmacological and immunological points of application. The emphasis of the mechanisms of action of such drugs is made on the effect on the systems of both innate and adaptive immunity. At the same time, the severity of the effect on both one and the other immune system in drugs that is strong enough may differ, which requires special attention from the doctor when choosing a drug in a particular situation. A special place in the group of immunomodulatory drugs used for infectious respiratory diseases is occupied by interferoncontaining drugs that contain interferon alfa-2b (IFN-a2b). In addition, there are combination of IFN-a2b with an immunoglobulin complex, which increases the effectiveness of this drug in the treatment of various infectious and inflammatory diseases. The article describes the theoretical and practical aspects of administration this combined drug in pediatric practice and presents own experimental studies.

show abstract

Potential of azoximere bromide for treatment of patients with acute inflammatory and infectious upper respiratory diseases

Svistushkin,

Nikiforova,

Eremeeva

et al. 2023

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Aim. To evaluate the efficacy and safety of Polyoxidonium® in patients with inflammatory and infectious upper respiratory diseases in real clinical practice.Materials and methods. This retrospective multicenter study included data from adults and children over 6 months old with inflammatory and infectious upper respiratory diseases (n=16 365). The exploratory endpoints included: the proportion of patients with complete relief of symptoms, demographic characteristics of patients, the frequency of prescriptions of Polyoxidonium® by disease groups, determination of the groups of concomitant drugs, most commonly prescribed treatment regimen, frequency of prescribing different Polyoxidonium® dosage forms, duration of the most common specific symptoms of acute respiratory infections during therapy, the incidence of treatment-related adverse events.Results. After treatment completion, the proportion of patients with complete relief of symptoms was 40%, with positive dynamics – 99.77%. Polyoxidonium® in combination therapy was also effective in the treatment of COVID-19 and Post-COVID-19 syndrome. The median patient age was 28 years. Polyoxidonium® was most frequently prescribed for the treatment of inflammatory and infectious upper respiratory diseases in combination with antibiotics or symptomatic drugs in dosage form solution. The primary routes of administration were intranasal and sublingual. The resolution of infection symptoms occurred predominantly within the first 5 days after the initiation of therapy. The therapy appeared to be equally effective across all age groups. No Polyoxidonium®-related adverse events occurred.Conclusion. Treatment with Polyoxidonium® contributes to achieving favorable outcomes in patients with inflammatory and infectious upper respiratory diseases. The study drug has a high safety profile.

show abstract

Immunomodulators for the prevention and treatment of acute respiratory infections: Efficacy of azoximer bromide

Cited by 5 publications

References 3 publications

Pharmacologic and Epidemiologic Study of the Course of Influenza and Other Acute Respiratory Viral Infections in Postpandemic Season in Children Younger than 18 years

Pharmacologic and Epidemiologic Study of the Course of Influenza and Other Acute Respiratory Viral Infections in Postpandemic Season in Children Younger than 18 years

Interferoncontaining drugs: clinical, pharmacological, and immunological points of their use for respiratory diseases treatment

Potential of azoximere bromide for treatment of patients with acute inflammatory and infectious upper respiratory diseases

Contact Info

Product

Resources

About